Outlive
LongevityResearchHub
Preliminary — 32/100 Review / Commentary PubMed

Simple Blood Tests May Help Predict COVID-19 Severity in Older Adults

The neutrophil-to-lymphocyte ratio as a marker of immunosenescence and COVID-19 outcomes in the elderly: A narrative review.

Physiological reports February 12, 2026 Gasmi Maha, Torabinasab Kimia, Williams-Hooker Ruth, Marsigliante Santo, Muscella Antonella
TL;DR

This narrative review examines whether three readily available blood markers—lymphopenia, neutrophilia, and the neutrophil-to-lymphocyte ratio (NLR)—can reliably indicate immune aging and predict severe COVID-19 outcomes in elderly patients. The authors conclude these markers consistently correlate with worse COVID-19 outcomes and offer a practical, low-cost way to identify high-risk older adults.

Credibility Assessment Preliminary — 32/100
Study Design
Rigor of the research methodology
4/20
Sample Size
Whether the study was sufficiently powered
2/20
Peer Review
Review status and journal reputation
11/20
Replication
Has this finding been independently reproduced?
7/20
Transparency
Funding disclosure and data availability
8/20
Overall
Sum of all five dimensions
32/100

What this means

Simple blood tests measuring immune cell ratios appear to correlate with COVID-19 severity in older adults and may reflect immune aging—a promising lead for cheap, practical risk screening. However, this is a preliminary review without rigorous methods; higher-quality studies are needed before clinicians should rely on these markers to guide treatment decisions.

Red Flags: Narrative review with no explicit methodology, protocol, or systematic inclusion/exclusion criteria—high bias risk. Zero citations despite publication date in 2026 raises questions about circulation. No data extraction tables, quality assessment of included studies, or effect size reporting. Future publication date is unusual and may indicate preprint status despite 'Is Preprint: False.' No mention of funding conflicts, but standard narrative reviews often lack transparent conflict-of-interest statements. 'Physiological Reports' is a legitimate peer-reviewed open-access journal (ISSN 2051-817X), but this work is synthesis only, not primary research.

The challenge: Older adults face disproportionately severe COVID-19 outcomes, and researchers have long suspected that age-related immune dysfunction ('immunosenescence') plays a key role. However, measuring immune aging typically requires specialized laboratory tests. This review asks a practical question: can simple, routine blood tests already performed in most hospitals serve as windows into immune aging and predict COVID-19 severity?

What they did: The authors conducted a narrative review (not a systematic review with pre-registered methods) of literature from PubMed, Scopus, and Web of Science through 2025, examining studies on aging, immunosenescence, and three hematological markers: lymphopenia (too few lymphocytes), neutrophilia (too many neutrophils), and the neutrophil-to-lymphocyte ratio (NLR—a simple calculation dividing neutrophil count by lymphocyte count).

What they found: The review concludes that all three markers consistently correlate with worse COVID-19 outcomes and that NLR is particularly promising as a simple, reliable indicator of systemic inflammation and mortality risk in older adults with COVID-19. The authors emphasize these markers are low-cost, readily measurable, and complement existing immunosenescence research.

Important limitations: This is a narrative review, not a systematic review, meaning the authors selected and interpreted papers without pre-specified protocols—introducing potential bias. The paper provides no detailed data tables, effect sizes, or rigorous quality assessment of included studies. Publication date is February 2026 (future-dated), and it currently has zero citations, raising questions about availability and peer-community engagement. The review cannot establish causation or explain *why* these markers correlate with severity, only that they do.

What this means for longevity research: If validated rigorously, NLR and related markers could offer a 'canary in the coal mine' for immune aging—a practical, inexpensive screening tool for clinical settings. However, this review is preliminary synthesis work, not definitive evidence. The real value lies in prompting higher-quality studies: prospective cohort studies with pre-registered protocols, mechanistic investigations of why immune imbalance worsens outcomes, and validation of NLR thresholds for risk stratification in diverse elderly populations.

The findings align with decades of immunosenescence research showing that aging dysregulates immune cell ratios, but a narrative review cannot prove these markers are causally linked to aging or sufficient for clinical decision-making. Clinicians should view NLR as one of many indicators, not a standalone predictor.

Biomarkers of Aging Blood Biomarkers Clinical Trials Regulatory Senescence
View Original Source

0 Comments